Subacute Cutaneous Lupus Erythematosus Induced by Spironolactone
Authors:
H. Tomková 1; Z. Drahotuská 1; L. Pock 2
Authors‘ workplace:
Kožní oddělení, Krajská nemocnice T. Bati, a. s., Zlín
primář MUDr. Jan Šternberský, CSc.
1; Histopatologická laboratoř, Praha
2
Published in:
Čes-slov Derm, 87, 2012, No. 4, p. 138-140
Category:
Pharmacologyand Therapy, Clinical Trials
Overview
Drug-induced lupus erythematosus is a reversible disease. Its symptoms are usually mild to moderate and complete resolution of clinical and serological findings follows the withdrawal of the particular drug. The authors describe a case of drug-induced subacute cutaneous lupus erythematosus in a 60-year-old woman which appeared about three months after commencement of the spironolactone therapy and regressed spontaneously within a month after its withdrawal.
Key words:
subacute cutaneous lupus erythematosus – drug-induced lupus – spironolactone
Sources
1. BREATHNACH, S. M.: Drug reactions. In: Burnss, T., Breathnach, S., Cox, N., Griffiths, C.: Rook’s textbook of Dermatology, Oxford: Blackwell Science, 2004, p. 73.1–73.180.
2. CETKOVSKÁ, P.: Kožní autoimunitní nemoci indukované léčbou. Čes-slov Derm, 2005, 80, s. 322–325.
3. CLARK, C., DOUGLAS, W. S.: Lichenoid drug eruption induced by spironolactone. Clin. Exp. Dermatol., 1998, 23, p. 43–48.
4. DALLE VEDOVE, C., DEL GIGLIO, M., SCHENA, D., GIROLOMONI, G.: Drug-induced lupus erythematosus. Arch. Dermatos. Res., 2009, 301, p. 99–105.
5. GISONDI, P., GIROLOMONI, G.: Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun. Rev., 2007, 6, p. 515–519.
6. GUPTA, A. K., KNOWLES, S. R., SHEAR, N. H.: Spironolactone--associated cutaneous effects: a case report and review of the literature. Dermatology, 1994, 189, p. 402–405.
7. MUTASIM, D. F., ADAMS, B. B.: Immunofluorescence in dermatology. J. Am. Acad. Dermatol., 2001, 45, p. 803–822.
8. RAHAMAN, A., ISENBERG, D. A.: Systemic lupus erythematosus. N. Engl. J. Med., 2008, 358, p. 929–939.
9. ŠTORK, J.: Poruchy vaziva. In ŠTORK, J. et al.: Dermatovenerologie. Praha: Galén, 2008, s. 213–234.
10. UDDIN, M. S., LYNFIELD, Y. L., GROSBERG, S. J., STIEFLER, R.: Cutaneous reaction to spironolactone resembling lupus erythematosus. Cutis, 1979, 24, p. 198–200.
11. VAN RIJTHOVEN, A. V. A. M., BIJLSMA, J. W. J., CANNINGA VAN DIJK, M. et al.: Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology, 2006, 45, p. 1317–1319.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2012 Issue 4
Most read in this issue
- Differential Diagnostics of Pruritus
- Allergic Reaction to Contact with Toxicodendron radicans
- Subacute Cutaneous Lupus Erythematosus Induced by Spironolactone
- Anogenital Lichen Sclerosus et Atrophicus in Children: Retrospective Analysis of Patients from the Years 2006–2010